SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : URMD -- Huge market potential
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Samuel J. Bennett who wrote (136)11/11/1997 11:56:00 AM
From: TheCat   of 369
 
With five FDA approved products and $80 million in cash, URMD is more than a development stage company. From here on, URMD is a value play. Granted the company has disappointed investors previously, but the Cavermap is the product that will change all of that. Like previous postings have pointed out, no one would want do undergo a prostate surgery without Cavermap.

Prior to the Cavermap analysts were expecting only $15 million in revenues. Now they are going to have to significantly raise their revenue estimates for 1998 along with their ratings on the URMD stock.

The managment of this company is very deliberate and this has been a positive and a negative. On the one hand they have built their stable of products, but on the other they have been slow to market them. Now that URMD has built its product line, trained its sales force, it should turn its efforts to marketing their products.

In the short term look for analyst upgrades and more HMO reimbursement anouncements to launch the stock.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News